Yes-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Esomeprazole 40mg, designed for the management of gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor, irreversibly inhibits the H+/K+ ATPase enzyme system in gastric parietal cells, leading to a significant reduction in gastric acid secretion. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, optimizing symptom control and improving patient compliance. Yes-D Capsule SR is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and other acid-related disorders, particularly in patients who require both acid suppression and prokinetic effects. It is contraindicated in patients with known hypersensitivity to either component, and caution is advised in those with hepatic impairment or cardiac arrhythmias. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. The combination therapy offers a synergistic approach to managing complex upper gastrointestinal conditions by addressing both acid hypersecretion and motility dysfunction.